{"id":"W4380083458","doi":"10.1002/hon.3164_446","title":"Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Tolerability; Obinutuzumab; Internal medicine; Rituximab; CHOP; Refractory (planetary science); Gastroenterology; Lymphoma; CD20; Oncology; Dosing; Phases of clinical research; Immunology; Adverse effect; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001990455,0.0004740196,0.001074857,0.0002427382,0.0001880971,0.001132272,0.0005998236,0.0005718109,0.002068306],"category_scores_gemma":[0.0007110707,0.0002251768,0.0009581284,0.0003837594,0.0003597684,0.0006404973,0.0002043808,0.001298867,0.0005819605],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000690608,"about_ca_system_score_gemma":0.0007244719,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006608769,"about_ca_topic_score_gemma":0.001712664,"domain_scores_codex":[0.9996934,0.0001226086,0.00003559454,0.0000322943,0.00004899298,0.00006710547],"domain_scores_gemma":[0.9994403,0.0001300965,0.0001504134,0.0000708726,0.00007968109,0.0001286856],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.105336,0.01415274,0.02018686,0.002414062,0.002120767,0.0003698572,0.0006435444,0.002042884,0.09005021,0.0004805852,0.01046427,0.7517383],"study_design_scores_gemma":[0.1485037,0.5831884,0.127201,0.0009851069,0.004986833,0.003928518,0.0004143922,0.002906046,0.03983814,0.0006635247,0.08723628,0.0001481016],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9636008,0.02754953,0.0008008377,0.0007779972,0.0001137219,0.0007938333,0.001119323,0.0001948756,0.005049077],"genre_scores_gemma":[0.975087,0.01629172,0.00150231,0.001638777,0.0001861455,0.0006475013,0.00302829,0.00006312058,0.001555316],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002068306,"threshold_uncertainty_score":0.01052666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03626881542327003,"score_gpt":0.3635415401709561,"score_spread":0.327272724747686,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}